General Information of This Antibody
Antibody ID
ANI0OAONZ
Antibody Name
Anti-CD46 fully human antibody
Synonyms
Anti-CD46 fully human antibody (ab)
   Click to Show/Hide
Antibody Type
Monoclonal antibody (mAb)
Antibody Subtype
Humanized IgG1
Antigen Name
Membrane cofactor protein (CD46)
 Antigen Info 
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
FOR-46 [Phase 1/2]
Identified from the Human Clinical Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Partial Response (PR)
22.20%
Patients Enrolled
Metastatic castration-resistant prostate cancer (CRPC).
Administration Dosage
Intravenous FOR46 on day 1 of every 21-day cycle. Dose levels ranged from 0.10 mg/kg. the starting dose level, to 3.00 mg/kg. The trial established 2.70 mg/kg to be the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of the agent.
Related Clinical Trial
NCT Number NCT03575819  Clinical Status Phase 1
Clinical Description
A phase 1 study of FOR46 administered every 21 days in patients with metastatic castration-resistant prostate cancer (mCRPC).
Primary Endpoint
MtD and phase 1b dose=2.70 mg/kg.
Other Endpoint
18 pts had measurable lesions; 8 of 18 (44.44%) had tumor regression, with 4 (22.22%) confirmed partial responses (PR). The median duration of response is > 14 wks (range 9 -31+ weeks).
Experiment 2 Reporting the Activity Date of This ADC [2]
Related Clinical Trial
NCT Number NCT05011188  Clinical Status Phase 1/2
Clinical Description
A phase 1b/2 study of FOR46 in combination with enzalutamide in patients with metastatic castration resistant prostate cancer.
Experiment 3 Reporting the Activity Date of This ADC [3]
Related Clinical Trial
NCT Number NCT03650491  Clinical Status Phase 1
Clinical Description
A phase 1 study of FOR46 administered every 21 days in patients with relapsed or refractory multiple myeloma (RRMM).
References
Ref 1 Phase 1a/1b study of FOR46, an antibody drug conjugate (ADC), targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology 40, no. 16_suppl (June 01, 2022) 3001-3001.
Ref 2 A Phase 1b/2 Study of FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer, NCT05011188
Ref 3 A Phase I Study of FOR46 Administered Every 21 Days in Patients With Relapsed or Refractory Multiple Myeloma (RRMM), NCT03650491

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.